In:
International Journal of Cancer, Wiley, Vol. 139, No. 10 ( 2016-11-15), p. 2359-2369
Abstract:
What's new? Targeting of receptor tyrosine kinases has emerged as a promising cancer treatment strategy. Here, the authors investigated the receptor tyrosine kinase DDR2 as a potential target in squamous cell carcinoma of the head and neck (HNSCC). Using for the first time a large and diverse cohort of patients, they showed that DDR2 is overexpressed in head and neck tumor tissue as compared to normal mucosa. Moreover, migration, invasion, and adhesion were increased in cell models and zebrafish xenografts and could be reduced by dasatinib, providing a rationale for clinical testing of the FDA‐approved inhibitor in patients with DDR2‐positive HNSCC tumors.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink